Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:CRDF NASDAQ:CYPH NASDAQ:NRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.66-0.1%$2.25$1.07▼$6.18$99.23M1.162.32 million shs245,318 shsCRDFCardiff Oncology$1.68-3.2%$1.72$1.48▼$4.56$114.52M1.36952,730 shs328,135 shsCYPHCypherpunk Technologies$1.12-6.7%$0.83$0.23▼$3.70$109.40M-0.092.88 million shs869,970 shsNRSNNeuroSense Therapeutics$0.84-1.4%$0.79$0.63▼$2.60$27.90M1.6184,071 shs16,789 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-2.35%-4.05%-7.26%-68.56%-23.50%CRDFCardiff Oncology+2.37%+8.12%+6.13%+8.12%-35.21%CYPHCypherpunk Technologies+15.38%+13.21%+26.32%+69.04%+193.40%NRSNNeuroSense Therapeutics+2.21%-2.98%+19.85%-18.18%-30.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.66-0.1%$2.25$1.07▼$6.18$99.23M1.162.32 million shs245,318 shsCRDFCardiff Oncology$1.68-3.2%$1.72$1.48▼$4.56$114.52M1.36952,730 shs328,135 shsCYPHCypherpunk Technologies$1.12-6.7%$0.83$0.23▼$3.70$109.40M-0.092.88 million shs869,970 shsNRSNNeuroSense Therapeutics$0.84-1.4%$0.79$0.63▼$2.60$27.90M1.6184,071 shs16,789 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-2.35%-4.05%-7.26%-68.56%-23.50%CRDFCardiff Oncology+2.37%+8.12%+6.13%+8.12%-35.21%CYPHCypherpunk Technologies+15.38%+13.21%+26.32%+69.04%+193.40%NRSNNeuroSense Therapeutics+2.21%-2.98%+19.85%-18.18%-30.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50231.53% UpsideCRDFCardiff Oncology 2.57Moderate Buy$10.10502.99% UpsideCYPHCypherpunk Technologies 1.00SellN/AN/ANRSNNeuroSense Therapeutics 2.60Moderate Buy$8.50913.11% UpsideCurrent Analyst Ratings BreakdownLatest NRSN, CRDF, CYPH, and ALDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026NRSNNeuroSense Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/22/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/8/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/25/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/18/2026ALDXAldeyra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $2.003/17/2026ALDXAldeyra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/17/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/10/2026NRSNNeuroSense Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.003/9/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.002/25/2026CRDFCardiff Oncology Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$10.00 ➝ $6.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.70 per shareN/ACRDFCardiff Oncology$590K194.10N/AN/A$0.67 per share2.50CYPHCypherpunk TechnologiesN/AN/AN/AN/A$1.83 per shareN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.05) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%N/ACRDFCardiff Oncology-$45.85M-$0.69N/AN/AN/A-7,733.22%-82.01%-64.09%7/30/2026 (Estimated)CYPHCypherpunk Technologies$4.82M$0.0716.00N/AN/AN/A-99.76%-79.44%5/18/2026 (Estimated)NRSNNeuroSense Therapeutics-$11.12M-$0.54N/AN/AN/AN/AN/AN/A6/22/2026 (Estimated)Latest NRSN, CRDF, CYPH, and ALDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CYPHCypherpunk Technologies-$0.0406-$0.46-$0.4194-$0.46N/AN/A5/14/2026Q1 2026CRDFCardiff Oncology-$0.13-$0.18-$0.05-$0.18$0.09 million$0.04 million5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/A2/27/2026Q4 2025ALDXAldeyra Therapeutics-$0.14-$0.1074+$0.0326-$0.10$24.25 millionN/A2/24/2026Q4 2025CRDFCardiff Oncology-$0.18-$0.11+$0.07-$0.11$0.13 million$0.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.722.72CRDFCardiff OncologyN/A3.673.67CYPHCypherpunk TechnologiesN/A35.5635.56NRSNNeuroSense TherapeuticsN/A0.310.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%CRDFCardiff Oncology16.29%CYPHCypherpunk Technologies30.46%NRSNNeuroSense Therapeutics1.04%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%CRDFCardiff Oncology7.70%CYPHCypherpunk Technologies3.50%NRSNNeuroSense Therapeutics27.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million54.53 millionOptionableCRDFCardiff Oncology2068.37 million63.11 millionOptionableCYPHCypherpunk Technologies4097.68 million94.26 millionOptionableNRSNNeuroSense Therapeutics1032.56 million23.64 millionNot OptionableNRSN, CRDF, CYPH, and ALDX HeadlinesRecent News About These CompaniesNeuroSense Secures Insider-Led $600,000 PIPE at Premium Share PriceApril 28, 2026 | tipranks.comNeuroSense Announces Pricing of Insider-Led PIPE FinancingApril 28, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Opus Genetics (IRD)April 9, 2026 | theglobeandmail.comNeuroSense Granted Brazilian Patent Covering PrimeC CompositionApril 6, 2026 | prnewswire.comNeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value RequirementsApril 3, 2026 | prnewswire.comNeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business UpdateMarch 31, 2026 | prnewswire.comNeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's ReadoutMarch 24, 2026 | prnewswire.comPrimeC New Data to Be Presented at AD/PD™ 2026 ConferenceMarch 18, 2026 | prnewswire.comNeuroSense: JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological ActivityMarch 16, 2026 | finanznachrichten.deJAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological ActivityMarch 16, 2026 | prnewswire.comRoth Capital initiates coverage of NeuroSense Therapeutics (NRSN) with buy recommendationMarch 11, 2026 | msn.comPrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific ConferenceMarch 9, 2026 | prnewswire.comNeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 14.7% – Time to Sell?February 19, 2026 | defenseworld.netDNeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALSFebruary 18, 2026 | prnewswire.comNeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital IncreaseFebruary 13, 2026 | tipranks.comNeurosense Therapeutics stock rises after securing Australian patent for PrimeCFebruary 11, 2026 | au.investing.comNeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC CompositionFebruary 9, 2026 | prnewswire.comNeuroSense Granted U.S. Patent for Treatment of Alzheimer's DiseaseJanuary 21, 2026 | prnewswire.comNeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve CashJanuary 17, 2026 | theglobeandmail.comWorld-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SABJanuary 8, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRSN, CRDF, CYPH, and ALDX Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$1.66 0.00 (-0.06%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Cardiff Oncology NASDAQ:CRDF$1.68 -0.06 (-3.18%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Cypherpunk Technologies NASDAQ:CYPH$1.12 -0.08 (-6.67%) As of 10:21 AM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.NeuroSense Therapeutics NASDAQ:NRSN$0.84 -0.01 (-1.40%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
